贝伐珠单抗联合腹腔热灌注治疗卵巢癌合并腹腔积液的疗效  

Effect of bevacizumab combined with intraperitoneal hyperthermic perfusion on ovarian cancer with ascites

作　　者：林平珍 郑国锋[1] 

机构地区：[1]山东省枣庄市妇幼保健院妇产科,枣庄277102

出　　处：《临床医学》2015年第8期49-50,共2页Clinical Medicine

摘　　要：目的探讨贝伐珠单抗联合腹腔热灌注治疗卵巢癌合并腹腔积液的临床疗效。方法选择2012年7月至2014年9月枣庄市妇幼保健院收治的卵巢癌并发腹腔积液患者47例,随机分为实验组24例和对照组23例。实验组使用深静脉软管经皮腹腔内置管,将顺铂和贝伐珠单抗经体外加热后灌注到腹腔内;对照组仅灌注顺铂,观察患者腹腔内恶性积液量的变化。同时检测患者肿瘤标志物的变化情况、一般情况和生活质量。结果行腹腔热灌注化疗后,47例患者中39例腹腔恶性积液减少量达50%以上,有效率达83%。加入贝伐珠单抗后患者肿瘤指标下降程度更明显。结论贝伐珠单抗腹腔热灌注治疗卵巢癌合并腹腔恶性积液近期疗效明显,且不良反应较直接化疗小,患者耐受程度高。Objective To investigate the clinical effect of bevacizumab combined with intraperitoneal hyperthermic perfusion on ovarian cancer with ascites. Methods We selected 47 cases of ovarian cancer compliated with ascites,they were randomly divided into experimental group（ n = 24） and Control group（ n = 23）. Deep venous hose percutaneous abdominal internal tube was used in the experimental group,cisplatin and bevacizumab was infused into the peritoneal cavity after in vitro heating; in the control group,only cisplatin was infused. The change of malignant effusion volume of the patients was observed. At the same time,the changes of tumor markers,the general condition and quality of life of these patients were detedcted. Results After intraperitoneal hyperthermic perfusion chemotherapy,there were 39 cases of abdominal malignant effusion reduced up to 50%,the effective rate was 83%. Adding bevacizumab,the tumor indexes reduced more obviously. Conclusion The short-term curative effect of bevacizumab intraperitoneal hyperthermic perfusion on ovarian carcinoma complicated with malignant abdominal effusions is remarkable,the side effects are less,and the tolerance is good.

关 键 词：贝伐珠 腹腔热灌注 卵巢癌 腹腔积液 

分 类 号：R737.31[医药卫生—肿瘤]